Zirconium-89 labeled antibodies: A new tool for molecular imaging in cancer patients

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Van De Watering, Floor C J ^a   Rijpkema, Mark ^a   Perk, Lars ^a   Brinkmann, Ulrich ^b   Oyen, Wim J G ^a   Boerman, Otto C ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ROCHE INNOVATION CENTER MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHELATING AGENT; UNCLASSIFIED DRUG; ZIRCONIUM 89; ZIRCONIUM DERIVATIVE; ANTIBODY; RADIOISOTOPE; ZIRCONIUM;

ARTICLE; CANCER PATIENT; CLINICAL STUDY; CONJUGATION; HUMAN; MOLECULAR IMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RADIOCHEMISTRY; CHEMISTRY; DIAGNOSTIC USE; NEOPLASM; PATHOLOGY; RADIOGRAPHY;

ANTIBODIES; HUMANS; MOLECULAR IMAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOISOTOPES; ZIRCONIUM;

EID: 84902178800     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/203601     Document Type: Article

References (108)

1. Zhang Y., Hong H., Cai W., PET tracers based on zirconium-89. Current Radiopharmaceuticals 2011 4 2 131 139 2-s2.0-79958265709 10.2174/ 1874471011104020131
2. Herbst R. S., Shin D. M., Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 2002 94 5 1593 1611 2-s2.0-0036500831 10.1002/cncr.10372 (Pubitemid 34212655)
3. 89Zr-trastuzumab PET. Journal of Nuclear Medicine 2013 54 6 936 943 2-s2.0-84878663006 10.2967/jnumed.112.110239
4. 111In-girentuximab uptake in patients with clear cell renal cell carcinoma. Journal of Nuclear Medicine 2014 55 2 242 247 10.2967/jnumed.113.131110
5. Wadas T. J., Wong E. H., Weisman G. R., Anderson C. J., Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease. Chemical Reviews 2010 110 5 2858 2902 2-s2.0-77952468760 10.1021/cr900325h
6. 86Y with PET. European Journal of Nuclear Medicine and Molecular Imaging 2011 38 supplement 1 S10 S18 2-s2.0-79957950078 10.1007/s00259-011-1768- 2
7. Link J. M., Krohn K. A., Eary J. F., Sixth international symposium on radiopharmaceutical chemistry. Abstracts. Part III. Journal of Labelled Compounds and Radiopharmaceuticals 1986 23 10-12 1297
8. 89Zr in a medical cyclotron for PET radiopharmaceuticals. Journal of Nuclear Medicine Technology 2013 41 1 35 41 2-s2.0-84874984571 10.2967/jnmt.112.111377
9. 89Zr-labeled monoclonal antibodies. Journal of Nuclear Medicine 2003 44 8 1271 1281 2-s2.0-0141669355 (Pubitemid 39662684)
10. 89Zr for the labelling of antibodies with a positron emitter. Applied Radiation and Isotopes 1994 45 12 1143 1147 2-s2.0-0028579717
11. Holland J. P., Sheh Y., Lewis J. S., Standardized methods for the production of high specific-activity zirconium-89. Nuclear Medicine and Biology 2009 36 7 729 739 2-s2.0-69249216426 10.1016/j.nucmedbio.2009.05.007
12. 89Zr. 1509 Proceedings of the 14th International Workshop on Targetry and Target Chemistry (WTTC '12) August 2012 Playa del Carmen, México 201 205 AIP Conference 2-s2.0-84874389043 10.1063/1.4773968
13. 89Zr separation module. 1509 Proceedings of the 14th International Workshop on Targetry and Target Chemistry (WTTC '12) August 2012 Playa del Carmen, México 206 210 AIP Conference 2-s2.0-84874379580 10.1063/1.4773969
14. 89Zr using an automated module. Applied Sciences 2013 3 3 593 613 10.3390/app3030593
15. Herscheid J. D. M., Vos C. M., Hoekstra A., Manganese-52m for direct application: a new 52Fe/52mMn generator based on a hydroxamate resin. The International Journal of Applied Radiation and Isotopes 1983 34 6 883 886 2-s2.0-0020766033 10.1016/0020-708X(83)90147-3 (Pubitemid 13078312)
16. 89Zr in mice. Nuclear Medicine and Biology 2011 38 5 675 681 2-s2.0-79959667363 10.1016/j.nucmedbio.2010.12.011
17. Al Lawati W. M., Jean J. S., Kulp T. R., Lee M., Polya D. A., Liu C., van Dongen B. E., Characterisation of organic matter associated with groundwater arsenic in reducing aquifers of Southwestern Taiwan. Journal of Hazardous Materials 2013 262 970 979 2-s2.0-84865755207 10.1016/j.jhazmat.2012.08.007
18. 90Y-Zevalin biodistribution with positron emission tomography. European Journal of Nuclear Medicine and Molecular Imaging 2006 33 11 1337 1345 2-s2.0-33750305681 10.1007/s00259-006-0160-0 (Pubitemid 44630790)
19. Kiss T., Farkas E., Metal-binding ability of desferrioxamine B. Journal of Inclusion Phenomena and Molecular Recognition in Chemistry 1998 32 2-3 385 403 2-s2.0-0032210212 (Pubitemid 128183424)
20. Meijs W. E., Herscheid J. D., Haisma H. J., Pinedo H. M., Evaluation of desferal as a bifunctional chelating agent for labeling antibodies with Zr-89. International Journal of Radiation Applications and Instrumentation A: Applied Radiation and Isotopes 1992 43 12 1443 1447 2-s2.0-0026472492 10.1016/0883-2889(92)90170-J
21. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. Journal of Nuclear Medicine 2010 51 8 1293 1300 2-s2.0-77956193105 10.2967/jnumed.110.076174
22. 89Zr: from radiochemistry to the clinic. Nuclear Medicine and Biology 2013 40 1 3 14 2-s2.0-84871928766 10.1016/j.nucmedbio.2012.08.004
23. Perk L., Vosjan M. W. D., Visser G. W., Budde M., Jurek P., Kiefer G. E., van Dongen G. A. M. S., p -isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging. European Journal of Nuclear Medicine and Molecular Imaging 2010 37 2 250 259 2-s2.0-77949268357 10.1007/s00259-009-1263-1
24. 89Zr(IV) complexation with hydroxamates: progress towards designing a better chelator than desferrioxamine B for immuno-PET imaging. Chemical Communications 2013 49 10 1002 1004 2-s2.0-84872054031 10.1039/c2cc37549d
25. Bhattacharyya S., Kurdziel K., Wei L., Riffle L., Kaur G., Hill G. C., Jacobs P. M., Tatum J. L., Doroshow J. H., Kalen J. D., Zirconium-89 labeled panitumumab: a potential immuno-PET probe for HER1-expressing carcinomas. Nuclear Medicine and Biology 2013 40 4 451 457 2-s2.0-84876734927 10.1016/j.nucmedbio.2013.01.007
26. 89Zr-PET radiochemistry in the development and application of therapeutic monoclonal antibodies and other biologicals. Current Topics in Medicinal Chemistry 2013 13 4 446 457 2-s2.0-84878795886 10.2174/1568026611313040005
27. 89Zr-desferrioxamine b-j591 anti-prostate-specific membrane antigen monoclonal antibody. Molecular Imaging and Contrast Agent Database (MICAD) 2004 Bethesda, Md, USA National Center for Biotechnology Information
28. 89Zr-labeled p -isothiocyanatobenzyl- desferrioxamine b (df-bz-ncs)-conjugated panitumumab, a fully human monoclonal antibody directed against the extracellular domain III of the epidermal growth factor receptor. Molecular Imaging and Contrast Agent Database (MICAD) 2004 Bethesda, Md, USA National Center for Biotechnology Information
29. 89Zr- trastuzumab for HER2/ neu immunoPET imaging. Journal of Nuclear Medicine 2009 50 6 974 981 2-s2.0-66649121433 10.2967/jnumed.108.060392
30. 89Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft. European Journal of Cancer 2010 46 3 678 684 2-s2.0-75149113119 10.1016/j.ejca.2009.12.009
31. 89Zr-labeled monoclonal antibodies for ImmunoPET. Nuclear Medicine and Biology 2010 37 3 289 297 2-s2.0-77950296003 10.1016/j.nucmedbio.2009.11.010
32. Zeglis B. M., Mohindra P., Weissmann G. I., Divilov V., Hilderbrand S. A., Weissleder R., Lewis J. S., Modular strategy for the construction of radiometalated antibodies for positron emission tomography based on inverse electron demand diels-alder click chemistry. Bioconjugate Chemistry 2011 22 10 2048 2059 2-s2.0-80054797650 10.1021/bc200288d
33. Vugts D. J., Vervoort A., Stigter-van Walsum M., Visser G. W. M., Robillard M. S., Versteegen R. M., Vulders R. C. M., Herscheid J. D. M., Van Dongen G. A. M. S., Synthesis of phosphine and antibody-azide probes for in vivo staudinger ligation in a pretargeted imaging and therapy approach. Bioconjugate Chemistry 2011 22 10 2072 2081 2-s2.0-80054800130 10.1021/bc200298v
34. Zeglis B. M., Davis C. B., Aggeler R., Kang H. C., Chen A., Agnew B. J., Lewis J. S., Enzyme-mediated methodology for the site-specific radiolabeling of antibodies based on catalyst-free click chemistry. Bioconjugate Chemistry 2013 24 6 1057 1067 2-s2.0-84879364396 10.1021/bc400122c
35. 89Zr, a radiometal nuclide with high potential for molecular imaging with pet: chemistry, applications and remaining challenges. Molecules 2013 18 6 6469 6490 2-s2.0-84879679457 10.3390/molecules18066469
36. Yeh H. H., Ogawa K., Balatoni J., Mukhapadhyay U., Pal A., Gonzalez-Lepera C., Shavrin A., Soghomonyan S., Flores L. II, Young D., Volgin A. Y., Najjar A. M., Krasnykh V., Tong W., Alauddin M. M., Gelovani J. G., Molecular imaging of active mutant L858R EGF receptor (EGFR) kinase-expressing nonsmall cell lung carcinomas using PET/CT. Proceedings of the National Academy of Sciences of the United States of America 2011 108 4 1603 1608 2-s2.0-79952126083 10.1073/pnas.1010744108
37. Natarajan A., Habte F., Gambhir S. S., Development of a novel long-lived immunoPET tracer for monitoring lymphoma therapy in a humanized transgenic mouse model. Bioconjugate Chemistry 2012 23 6 1221 1229 2-s2.0-84862692417 10.1021/bc300039r
38. Webb D. S., Shimizu Y., van Seventer G. A., Shaw S., Gerrard T. L., LFA-3, CD44, and CD45: physiologic triggers of human monocyte TNF and IL-1 release. Science 1990 249 4974 1295 1297 2-s2.0-0025185580
39. Mulder J. W., Kruyt P. M., Sewnath M., Oosting J., Seldenrijk C. A., Weidema W. F., Offerhaus G. J. A., Pals S. T., Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins. The Lancet 1994 344 8935 1470 1472 2-s2.0-0028131614 10.1016/S0140-6736(94)90290-9 (Pubitemid 24351702)
40. 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice. Journal of Nuclear Medicine 2003 44 10 1663 1670 2-s2.0-0642372172 (Pubitemid 40003744)
41. Verel I., Visser G. W., Boerman O. C., Van Eerd J. E. M., Finn R., Boellaard R., Vosjan M. J. W. D., Stigter-Van Walsum M., Snow G. B., Van Dongen G. A. M. S., Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET. Cancer Biotherapy and Radiopharmaceuticals 2003 18 4 655 661 2-s2.0-12444280048 (Pubitemid 37082386)
42. 89Zr-labeled anti-CD44 monoclonal antibody RG7356 in mice and cynomolgus monkeys: prelude to phase 1 clinical studies. MAbs 2013 6 2 567 575 10.4161/mabs.27415
43. Meric-Bernstam F., Hung M.-C., Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy. Clinical Cancer Research 2006 12 21 6326 6330 2-s2.0-33751295869 10.1158/1078-0432.CCR-06-1732 (Pubitemid 44799700)
44. Burstein H. J., The distinctive nature of HER2-positive breast cancers. The New England Journal of Medicine 2005 353 16 1652 1654 2-s2.0-26844457534 10.1056/NEJMp058197 (Pubitemid 41464703)
45. Hoeben B. A. W., Molkenboer-Kuenen J. D. M., Oyen W. J. G., Peeters W. J. M., Kaanders J. H. A. M., Bussink J., Boerman O. C., Radiolabeled cetuximab: dose optimization for epidermal growth factor receptor imaging in a head-and-neck squamous cell carcinoma model. International Journal of Cancer 2011 129 4 870 878 2-s2.0-79959708966 10.1002/ijc.25727
46. Koi L., Bergmann R., Brüchner K., Radiolabeled anti-EGFR-antibody improves local tumor control after external beam radiotherapy and offers theragnostic potential. Radiotherapy and Oncology 2014 110 2 362 369 10.1016/j.radonc.2013.12.001
47. Specenier P., Vermorken J. B., Cetuximab: its unique place in head and neck cancer treatment. Biologics 2013 7 1 77 90 2-s2.0-84876232194 10.2147/BTT.S43628
48. Jones C., Taylor M. A., McWilliams B., The role of cetuximab as first-line treatment of colorectal liver metastases. HPB 2013 15 1 11 17 2-s2.0-84870895981 10.1111/j.1477-2574.2012.00591.x
49. Boyd K., Shea S. M., Patterson J., Cetuximab for treatment of advanced squamous cell carcinoma in solid organ transplant recipients. Wiener Medizinische Wochenschrift 2013 163 15-16 372 375 2-s2.0-84879230469 10.1007/s10354-013-0213-5
50. Unger K., Niehammer U., Hahn A., Goerdt S., Schumann M., Thum S., Schepp W., Treatment of metastatic colorectal cancer with cetuximab: influence on the quality of life. Zeitschrift für Gastroenterologie 2013 51 8 733 739 2-s2.0-84882790613 10.1055/s-0033-1335064
51. 177Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab. Journal of Nuclear Medicine 2005 46 11 1898 1906 2-s2.0-33644827799 (Pubitemid 46196653)
52. 89Zr-labeled cetuximab uptake assessed with PET. Journal of Nuclear Medicine 2009 50 1 123 131 2-s2.0-58249105735 10.2967/jnumed.108.054312
53. Wu M., Rivkin A., Pham T., Panitumumab: human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer. Clinical Therapeutics 2008 30 1 14 30 2-s2.0-45349097237 10.1016/j.clinthera.2008.01.014 (Pubitemid 351843429)
54. Day K. E., Sweeny L., Kulbersh B., Zinn K. R., Rosenthal E. L., Preclinical comparison of near-infrared-labeled cetuximab and panitumumab for optical imaging of head and neck squamous cell carcinoma. Molecular Imaging and Biology 2013 15 6 722 729 2-s2.0-84878145142 10.1007/s11307-013-0652-9
55. 89Zr-labeled panitumumab for immuno-positron emission tomographic imaging of the epidermal growth factor receptor. Molecular Imaging 2013 12 1 17 27 2-s2.0-84877307347
56. Shan L., Activatable alexa fluor680-conjugated panitumumab and indocyanine green-conjugated trastuzumab cocktail. Molecular Imaging and Contrast Agent Database (MICAD) 2004 Bethesda, Md, USA National Center for Biotechnology Information
57. 111In-labeled panitumumab, a fully human monoclonal antibody directed against the extracellular domain III of the epidermal growth factor receptor. Molecular Imaging and Contrast Agent Database (MICAD) 2004 Bethesda, Md, USA National Center for Biotechnology Information
58. 2 fragment of panitumumab for molecular imaging and therapy of HER1-positive cancers. EJNMMI Research 2011 1 1 1 15 2-s2.0-84863233334 10.1186/2191-219X-1-1
59. 89Zr-panitumumab as a positron emission tomography biomarker for evaluating epidermal growth factor receptor-targeted therapy. Journal of Labelled Compounds and Radiopharmaceuticals 2014 57 1 25 35 10.1002/jlcr.3134
60. Gross M. E., Shazer R. L., Agus D. B., Targeting the HER-kinase axis in cancer. Seminars in Oncology 2004 31 1 supplement 3 9 20 2-s2.0-2142700147 (Pubitemid 38543936)
61. 89Zr-radiolabeled trastuzumab imaging in orthotopic and metastatic breast tumors. Pharmaceuticals 2012 5 1 79 93 2-s2.0-84856261443 10.3390/ph5010079
62. 89Zr-DFO-trastuzumab. PLoS ONE 2010 5 1 2-s2.0-77749309983 10.1371/journal.pone.0008859 e8859
63. 2 uptake in SKBR3 tumor xenografts. Molecular Pharmaceutics 2012 9 11 2995 3002 2-s2.0-84868579267 10.1021/mp3002182
64. Moreira I. S., Fernandes P. A., Ramos M. J., Vascular endothelial growth factor (VEGF) inhibition: a critical review. Anti-Cancer Agents in Medicinal Chemistry 2007 7 2 223 245 2-s2.0-33947123052 10.2174/187152007780058687 (Pubitemid 46403586)
65. Lin J., Kelly W. K., Targeting angiogenesis as a promising modality for the treatment of prostate cancer. Urologic Clinics of North America 2012 39 4 547 560 2-s2.0-84867690624 10.1016/j.ucl.2012.07.010
66. Maru D., Venook A. P., Ellis L. M., Predictive biomarkers for bevacizumab: are we there yet? Clinical Cancer Research 2013 19 11 2824 2827 2-s2.0-84878979173 10.1158/1078-0432.CCR-12-3409
67. Schweizer M. T., Carducci M. A., From bevacizumab to tasquinimod: angiogenesis as a therapeutic target in prostate cancer. Cancer Journal 2013 19 1 99 106 2-s2.0-84873865047 10.1097/PPO.0b013e31827e0b86
68. Argiris A., Kotsakis A. P., Hoang T., Worden F. P., Savvides P., Gibson M. K., Gyanchandani R., Blumenschein G. R., Chen H. X., Grandi J. R., Harari P. M., Kies M. S., Kim S., Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck. Annals of Oncology 2013 24 1 220 225 2-s2.0-84871554687 10.1093/annonc/mds245
69. Chan J. A., Stuart K., Earle C. C., Clark J. W., Bhargava P., Miksad R., Blaszkowsky L., Enzinger P. C., Meyerhardt J. A., Zheng H., Fuchs C. S., Kulke M. H., Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. Journal of Clinical Oncology 2012 30 24 2963 2968 2-s2.0-84865171421 10.1200/JCO.2011.40.3147
70. Kroep J. R., Nortier J. W., The role of bevacizumab in advanced epithelial ovarian cancer. Current Pharmaceutical Design 2012 18 25 3775 3783 2-s2.0-84867532761 10.2174/138161212802002689
71. Morris P. G., Bevacizumab is an active agent for recurrent high-grade glioma, but do we need randomized controlled trials? Anti-Cancer Drugs 2012 23 6 579 583 2-s2.0-84861819039 10.1097/CAD.0b013e3283528847
72. Sato S., Itamochi H., Bevacizumab and ovarian cancer. Current Opinion in Obstetrics and Gynecology 2012 24 1 8 13 2-s2.0-84855809821 10.1097/GCO. 0b013e32834daeed
73. Nagengast W. B., de Vries E. G., Hospers G. A., Mulder N. H., De Jong J. R., Hollema H., Brouwers A. H., Van Dongen G. A., Perk L. R., Lub-de Hooge M. N., In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. Journal of Nuclear Medicine 2007 48 8 1313 1319 2-s2.0-34547736456 10.2967/jnumed.107.041301 (Pubitemid 47242797)
74. 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. Journal of Nuclear Medicine 2010 51 5 761 767 2-s2.0-77952302437
75. 89Zr-bevacizumab PET as an early biomarker for the antiangiogenic effect of everolimus treatment in an ovarian cancer xenograft model. Clinical Cancer Research 2012 18 22 6306 6314 2-s2.0-84869213195 10.1158/1078-0432.CCR-12-0406
76. Nagengast W. B., Lub-de Hooge M. N., Oosting S. F., Den Dunnen W. F. A., Warnders F., Brouwers A. H., De Jong J. R., Price P. M., Hollema H., Hospers G. A. P., Elsinga P. H., Hesselink J. W., Gietema J. A., De Vries E. G. E., VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment. Cancer Research 2011 71 1 143 153 2-s2.0-78651397295 10.1158/0008-5472.CAN-10-1088
77. Carmeliet P., Moons L., Luttun A., Vincenti V., Compernolle V., De Mol M., Wu Y., Bono F., Devy L., Beck H., Scholz D., Acker T., Dipalma T., Dewerchin M., Noel A., Stalmans I., Barra A., Blacher S., Vandendriessche T., Ponten A., Eriksson U., Plate K. H., Foidart J., Schaper W., Charnock-Jones D. S., Hicklin D. J., Herbert J., Collen D., Persico M. G., Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nature Medicine 2001 7 5 575 583 2-s2.0-19244379078 10.1038/87904 (Pubitemid 32448325)
78. Rakic J. M., Lambert V., Devy L., Luttun A., Carmeliet P., Claes C., Nguyen L., Foidart J., Noël A., Munaut C., Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Investigative Ophthalmology and Visual Science 2003 44 7 3186 3193 2-s2.0-0037900481 10.1167/iovs.02-1092 (Pubitemid 36759791)
79. 89Zr-labeled PlGF antibody RO5323441. Journal of Nuclear Medicine 2013 54 6 929 935 2-s2.0-84878648598 10.2967/jnumed.112.112086
80. Osborne J. R., Akhtar N. H., Vallabhajosula S., Anand A., Deh K., Tagawa S. T., Prostate-specific membrane antigen-based imaging. Urologic Oncology 2013 31 2 144 154 2-s2.0-84875271267 10.1016/j.urolonc.2012.04.016
81. Zhang Y., Guo Z., Du T., Chen J., Wang W., Xu K., Lin T., Huang H., Prostate specific membrane antigen (PSMA): a novel modulator of p38 for proliferation, migration, and survival in prostate cancer cells. Prostate 2013 73 8 835 841 2-s2.0-84876901422 10.1002/pros.22627
82. 68Ga]gallium- labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. European Journal of Nuclear Medicine and Molecular Imaging 2013 40 4 486 495 2-s2.0-84879926196 10.1007/s00259-012-2298-2
83. Manyak M. J., Indium-111 capromab pendetide in the management of recurrent prostate cancer. Expert Review of Anticancer Therapy 2008 8 2 175 181 2-s2.0-40749110135 10.1586/14737140.8.2.175 (Pubitemid 351385907)
84. 89Zr-labeled human anti-CD147 monoclonal antibody as a positron emission tomography probe in a mouse model of pancreatic cancer. PLoS ONE 2013 8 4 2-s2.0-84875933701 10.1371/journal.pone.0061230 e61230
85. Weidle U. H., Scheuer W., Eggle D., Klostermann S., Stockinger H., Cancer-related issues of CD147. Cancer Genomics and Proteomics 2010 7 3 157 169 2-s2.0-77954112457
86. Riethdorf S., Reimers N., Assmann V., Kornfeld J., Terracciano L., Sauter G., Pantel K., High incidence of EMMPRIN expression in human tumors. International Journal of Cancer 2006 119 8 1800 1810 2-s2.0-33748485131 10.1002/ijc.22062 (Pubitemid 44356836)
87. Zucker S., Hymowitz M., Rollo E. E., Mann R., Conner C. E., Cao J., Foda H. D., Tompkins D. C., Toole B. P., Tumorigenic potential of extracellular matrix metalloproteinase inducer. The American Journal of Pathology 2001 158 6 1921 1928 2-s2.0-0034976637 (Pubitemid 32545174)
88. Chen Z. N., Mi L., Xu J., Song F., Zhang Q., Zhang Z., Xing J., Bian H., Jiang J., Wang X., Shang P., Qian A., Zhang S., Li L., Li Y., Feng Q., Yu X., Feng Y., Yang X., Tian R., Wu Z., Leng N., Mo T., Kuang A., Tan T., Li Y., Liang D., Lu W., Miao J., Xu G., Zhang Z., Nan K., Han J., Liu Q., Zhang H., Zhu P., Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: clinical phase I/II trials. International Journal of Radiation Oncology Biology Physics 2006 65 2 435 444 2-s2.0-33646251826 10.1016/j.ijrobp.2005.12.034
89. Zhang Z., Bian H., Feng Q., Mi L., Mo T., Kuang A., Tan T., Li Y., Lu W., Zhang Y., Zhang M., Tian R., Chen Z., Zhu P., Biodistribution and localization of iodine-131-labeled Metuximab in patients with hepatocellular carcinoma. Cancer Biology and Therapy 2006 5 3 318 322 2-s2.0-33646423320
90. Xu J., Shen Z. Y., Chen X. G., Zhang Q., Bian H., Zhu P., Xu H., Song F., Yang X., Mi L., Zhao Q., Tian R., Feng Q., Zhang S., Li Y., Jiang J., Li N., Yu X., Zhang Z., Chen Z., A randomized controlled trial of licartin for preventing hepatoma recurrence after liver transplantation. Hepatology 2007 45 2 269 276 2-s2.0-33847759950 10.1002/hep.21465 (Pubitemid 46374583)
91. Swietach P., Hulikova A., Vaughan-Jones R. D., Harris A. L., New insights into the physiological role of carbonic anhydrase IX in tumour pH regulation. Oncogene 2010 29 50 6509 6521 2-s2.0-78650308850 10.1038/onc.2010.455
92. 2 in head and neck tumors. Journal of Nuclear Medicine 2010 51 7 1076 1083 2-s2.0-77955001665 10.2967/jnumed.109.073189
93. 89Zr-Labeled Anti-CAIX monoclonal antibody cG250 in mice. Cancer Biotherapy & Radiopharmaceuticals 2013 28 7 510 515 2-s2.0-84881465677 10.1089/cbr.2013.1487
94. Heskamp S., Van Laarhoven H. W., Molkenboer-Kuenen J. D., Franssen G. M., Versleijen-Jonkers Y. M. H., Oyen W. J. G., Van Der Graaf W. T. A., Boerman O. C., ImmunoSPECT and immunoPET of IGF-1R expression with the radiolabeled antibody R1507 in a triple-negative breast cancer model. Journal of Nuclear Medicine 2010 51 10 1565 1572 2-s2.0-79851482773 10.2967/jnumed.110.075648
95. Jagoda E. M., Lang L., Bhadrasetty V., Histed S., Williams M., Kramer-Marek G., Mena E., Rosenblum L., Marik J., Tinianow J. N., Merchant M., Szajek L., Paik C., Cecchi F., Raffensperger K., Jose-Dizon J., Bottaro D. P., Choyke P., Immuno-PET of the hepatocyte growth factor receptor met using the 1-armed antibody onartuzumab. Journal of Nuclear Medicine 2012 53 10 1592 1600 2-s2.0-84867078746 10.2967/jnumed.111.102293
96. 89Zr-labelled monoclonal antibody DN30. European Journal of Nuclear Medicine and Molecular Imaging 2008 35 10 1857 1867 2-s2.0-52449133141 10.1007/s00259-008-0774-5
97. 89Zr PET imaging of hepatocellular carcinoma. Journal of Nuclear Medicine 2014 55 5 799 804 10.2967/jnumed.113.132118
98. Seitchik J. L., Peeler J. C., Taylor M. T., Blackman M. L., Rhoads T. W., Cooley R. B., Refakis C., Fox J. M., Mehl R. A., Genetically encoded tetrazine amino acid directs rapid site-specific in vivo bioorthogonal ligation with trans-cyclooctenes. Journal of the American Chemical Society 2012 134 6 2898 2901 2-s2.0-84856873462 10.1021/ja2109745
99. Börjesson P. K., Jauw Y. W., Boellaard R., de Bree R., Comans E. F. I., Roos J. C., Castelijns J. A., Vosjan M. J. W. D., Kummer J. A., Leemans C. R., Lammertsma A. A., Van Dongen G. A. M. S., Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients. Clinical Cancer Research 2006 12 7, part 1 2133 2140 2-s2.0-33646241548 10.1158/1078-0432.CCR-05-2137
100. 89Zr-ibritumomab tiuxetan and PET. European Journal of Nuclear Medicine and Molecular Imaging 2012 39 3 512 520 2-s2.0-84859648576 10.1007/s00259-011-2008-5
101. 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clinical Pharmacology and Therapeutics 2010 87 5 586 592 2-s2.0-77951474500 10.1038/clpt.2010.12
102. Bruno R., Washington C. B., Lu J., Lieberman G., Banken L., Klein P., Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. Cancer Chemotherapy and Pharmacology 2005 56 4 361 369 2-s2.0-23244455101 10.1007/s00280-005-1026-z (Pubitemid 41095399)
103. 89Zr-bevacizumab PET imaging in primary breast cancer. Journal of Nuclear Medicine 2013 54 7 1014 1018 2-s2.0-84879942864 10.2967/jnumed.112. 117218
104. 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients. Journal of Nuclear Medicine 2009 50 11 1828 1836 2-s2.0-70350736124 10.2967/jnumed.109.065862
105. 111In or 99Tcm. Nuclear Medicine Communications 1998 19 8 743 751 2-s2.0-0031700909 (Pubitemid 28407505)
106. Terwisscha van Scheltinga A. G. T., van Dam G. M., Nagengast W. B., Ntziachristos V., Hollema H., Herek J. L., Schröder C. P., Kosterink J. G. W., Lub-de Hoog M. N., De Vries E. G. E., Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies. Journal of Nuclear Medicine 2011 52 11 1778 1785 2-s2.0-80455168416 10.2967/jnumed.111.092833
107. 89Zr and IRDye 800CW. Molecular Pharmaceutics 2012 9 8 2339 2349 2-s2.0-84864706767 10.1021/mp300277f
108. 89Zr and IRDye 800CW. American Journal of Translational Research 2012 4 3 333 346 2-s2.0-84864964195